Treatment of Metastatic HER2-Positive Breast Cancer

Podcast

Dr Kaklamani and colleagues highlight key clinical trials such as DESTINY-Breast01, HER2CLIMB, NALA, and SOPHIA in the setting of advanced HER2-positive breast cancer and discuss the practical considerations of these data.

Related Videos
Parul N Barry, MD,
Erin Frances Cobain, MD
Erin Frances Cobain, MD
Video 6 - "Shared Decision Making and Multidisciplinary Collaboration in the Evolving HR+/HER2- Early-Stage Breast Cancer Landscape"
Manmeet Singh Ahluwalia, MD
Rita Nanda, MD
Video 5 - "AE Management with CDK4/6 Inhibitors: Strategies for Treatment Continuity and Optimal Patient Outcomes"
Rita Nanda, MD
Siddartha Yadav, MD, FACP
Nan Chen, MD
Related Content
consultant medical oncologist at Portsmouth Hospital NHS Trust

NICE Recommends Oncotype DX for Guiding Chemotherapy Decisions in Early-Stage, HR+/HER2– Breast Cancer

May 10th 2024
Article
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, professor, division head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; codirector, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute

Kummar on the Investigation of Rezatapopt in TP53 Y220C–Mutated Advanced Solid Tumors

May 9th 2024
Podcast
Nathalie LeVasseur, MD, FRCPC

Health Canada Approves Goserelin Acetate for High-Risk, ER+ Early and Advanced Breast Cancer

May 8th 2024
Article
Andre H. Goy, MD, vice president, physician in chief, Oncology Care Transformation Services, chairman, chief physician officer, chief, Lymphoma Division, John Theurer Cancer Center at Hackensack University Medical Center; Lydia Pfund Chair for Lymphoma, academic chairman, Oncology, Hackensack Meridian School of Medicine; professor, medicine, Georgetown University

Goy Gives Insights Into the Future Management of Lymphoma and Multiple Myeloma

May 6th 2024
Podcast
3d rendered illustration - breast cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

Final USPSTF Recommendation Statement Advises Women Begin Receiving Mammograms at 40 Years Old

May 1st 2024
Article
Erin Frances Cobain, MD

The Road Beyond Frontline CDK4/6 Inhibitors in HR+/HER2– Metastatic Breast Cancer Examines Combinations

April 30th 2024
Article